Biomed Watch
Industry analysis for policy, import-export platforms, medtech, clinical development, and global regulatory movement. This section is for market context, not medical advice.
What This Section Does
Policy & Platforms
China biomed policy, import-export infrastructure, and regional platform releases.
Global Regulation
FDA, EMA, WHO, and reputable industry sources with dates and source boundaries.
Market Signals
Clinical milestones, medical-device commercialization, financing, and cross-border implications.
Editorial Focus
- Shenzhen biomed import-export platform: what bottleneck does it remove?
- China vs global medtech signals: what changed this week
- How to read regulatory updates without turning them into medical advice
Quality Rule
FYZSXNB is traffic-first, but not volume-at-any-cost. A confirmed topic becomes a draft only after source checks, keyword review, useful structure, and a quality gate. WeChat, scoops, and community posts are leads, not copy sources.
Last section review: 2026-07-21.
FDA GUDID and AccessGUDID Procurement Verification Guide: DI Fields and Premarket Cross-Checks
Use FDA GUDID and AccessGUDID to verify device identity, then cross-check authorization and establishment registration in separate FDA databases.
Read more
Tongue-Swab Tuberculosis Diagnostic Accuracy: Evidence Appraisal of a Multicenter Study and Public Health Deployment Boundaries
A 689-participant study found 84.1% tongue-swab sensitivity versus a composite reference and 99.7% specificity. Review the evidence limits.
Read more
FDA Establishment Registration Verification Guide
Verify FDA establishment registration and device listing with this 4-step CDRH database audit workflow for medical device exporters and buyers.
Read more
国家药监局第21号公告UDI实施解读：2027二类器械与一类IVD赋码、数据库上传及医保代码对接（已纳入医保代码数据库的产品适用）
2026年第21号公告规定2027年6月1日起全部二类器械及一类IVD须具备UDI并完成数据库上传；已纳入医保代码数据库的产品须完成医保代码对接。本文深度解读合规要求与四大误区。
Read more
村卫生室CRP与SAA联合POCT对抗生素处方率影响评估
湖北仙桃40家村卫生室簇随机对照试验表明综合干预包将ARI抗生素处方率从67.51%降至50.70%，检测使用率仅7.4%。
Read more
FDA Foreign Drug Establishment Registration Guide
FDA foreign drug establishment registration: timing, site DUNS, U.S. agent and importers, annual renewal, SPL filing and approval boundaries.
Read more
FDA Labeler Code Checklist for Foreign Companies
FDA labeler code checklist covering DUNS, SPL submission routes, the 30-day update scope, and conditional two-year deactivation.
Read more
FXR0906 Clinical Trial China: Fosun Evidence Check
FXR0906 clinical trial China: what Fosun reported about NMPA clinical-trial approval, what remains unknown about Phase 1, and evidence boundaries.
Read more
FDA Global Generic Drug Affairs: Overseas Team Guide
What FDA Global Generic Drug Affairs does and does not do: Generic Drug Cluster, PSA pilot, and ANDA submission boundaries for overseas teams.
Read more
FDA Drug Registration and Listing: A Pre-Workshop Compliance Map for Manufacturers
FDA drug registration and listing compliance map: current SPL, EDRLS, and 510(j)(3) duties, plus the future 12-digit NDC timeline.
Read more
GDUFA III Controlled Correspondence: Scope, Submission Rules, and Eligibility Map for Generic Drug Developers
GDUFA III decision map for generic drug developers: controlled vs general correspondence, pre-ANDA meetings, post-CRL, PSG, and CPA boundaries.
Read more
Cell and Gene Therapy BLA Readiness: What FDA’s OTP Town Hall Transcript Clarifies
FDA transcript-backed guide to CGT BLA filing readiness: pre-BLA meetings, CBER checklists, eCTD validation, and refuse-to-file prevention.
Read more